Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.55B | 1.43B | 1.25B | 1.03B | 666.20M |
Gross Profit | 772.70M | 493.70M | 611.90M | 495.40M | 321.60M |
EBITDA | 222.20M | 197.40M | 183.40M | 75.10M | 99.70M |
Net Income | -59.40M | -85.60M | -16.60M | -160.40M | -157.10M |
Balance Sheet | |||||
Total Assets | 3.38B | 3.29B | 3.38B | 2.84B | 2.57B |
Cash, Cash Equivalents and Short-Term Investments | 79.50M | 39.00M | 110.50M | 141.80M | 101.50M |
Total Debt | 1.37B | 1.35B | 1.37B | 1.15B | 1.65B |
Total Liabilities | 1.61B | 1.55B | 1.59B | 1.32B | 1.99B |
Stockholders Equity | 1.77B | 1.74B | 1.79B | 1.51B | 584.00M |
Cash Flow | |||||
Free Cash Flow | 147.10M | 123.80M | 106.00M | 36.80M | -52.40M |
Operating Cash Flow | 194.20M | 153.40M | 138.60M | 55.10M | -35.20M |
Investing Cash Flow | -170.80M | -172.10M | -419.80M | -262.90M | -151.30M |
Financing Cash Flow | 16.50M | -52.30M | 247.50M | 248.10M | 202.60M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | C$1.13B | 13.68 | 65.09% | 3.78% | 8.68% | 39.93% | |
70 Outperform | C$1.19B | 30.45 | -14.61% | ― | 17.19% | -191.01% | |
67 Neutral | C$1.71B | 46.29 | 6.94% | 5.09% | 10.13% | 1.30% | |
64 Neutral | C$1.60B | ― | -2.58% | 0.62% | 9.94% | 35.48% | |
53 Neutral | C$183.36M | ― | -2.17% | ― | -0.16% | 75.25% | |
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.76% | -2.28% | |
― | $197.45M | 2.12 | 41.13% | 2.44% | ― | ― |
Dentalcorp Holdings reported strong financial results for the second quarter of 2025, with revenue increasing by 8.9% to $435.2 million and Adjusted EBITDA growing by 9.9% to $81.2 million compared to the same period in 2024. The company also expanded its national presence by acquiring eight new practice locations, contributing to a record Adjusted Free Cash Flow of $45.6 million and a decrease in net debt ratio, indicating robust operational performance and strategic growth.
The most recent analyst rating on (TSE:DNTL) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on dentalcorp Holdings stock, see the TSE:DNTL Stock Forecast page.
Dentalcorp Holdings Ltd., a leading network of dental practices in Canada and North America, announced its participation in several upcoming investor conferences in September 2025. These events, including the Morgan Stanley Global Healthcare Conference and the Jefferies Healthcare Services Conference, provide an opportunity for Dentalcorp to showcase its growth and strategic initiatives, potentially enhancing its industry positioning and stakeholder engagement.
The most recent analyst rating on (TSE:DNTL) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on dentalcorp Holdings stock, see the TSE:DNTL Stock Forecast page.
Dentalcorp Holdings Ltd., a leading network of dental practices in Canada and North America, has declared a dividend of $0.025 per share, payable on July 22, 2025, to shareholders of record as of July 3, 2025. The company also announced that it will release its second-quarter 2025 financial results on August 8, 2025, followed by a conference call to provide a business update, which may influence stakeholder perceptions and market positioning.
The most recent analyst rating on (TSE:DNTL) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on dentalcorp Holdings stock, see the TSE:DNTL Stock Forecast page.
Dentalcorp Holdings Ltd., a leading network of dental practices in Canada and North America, announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and Canaccord Genuity’s Annual Growth Conference. This participation underscores Dentalcorp’s commitment to engaging with investors and stakeholders, potentially enhancing its industry positioning and growth prospects.
The most recent analyst rating on (TSE:DNTL) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on dentalcorp Holdings stock, see the TSE:DNTL Stock Forecast page.
Dentalcorp Holdings announced the results of its Annual General and Special Meeting of Shareholders, where all nominated directors were elected, Ernst & Young LLP was re-appointed as auditors, and amendments to the company’s Equity Incentive Plan, Legacy Option Plan, and Deferred Share Unit were approved. These decisions reflect the company’s strategic focus on strengthening its governance and operational framework, potentially enhancing its position in the dental industry and providing growth opportunities for stakeholders.
The most recent analyst rating on (TSE:DNTL) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on dentalcorp Holdings stock, see the TSE:DNTL Stock Forecast page.